This page shows the latest tislelizumab news and features for those working in and with pharma, biotech and healthcare.
Moreover, tislelizumab was associated with higher objective response rate – 14.3% versus 5.4% – and more durable responses – 36.1 months versus 11 months – compared with sorafenib. ... Through a collaboration and licence agreement with BeiGene in
The safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported. ... Tislelizumab is a humanised immunoglobulin G4 monoclonal antibody designed to minimise binding to Fc gamma receptors on macrophages,
Last month, BeiGene announced positive results from a phase 3 trial showing tislelizumab plus chemotherapy significantly improved overall survival for patients with advanced esophageal cancer, regardless of PD-L1 status.
Results from the study showed tislelizumab plus chemotherapy significantly improved overall survival for patients, regardless of PD-L1 status. ... Through a collaboration and licence agreement with BeiGene, Novartis has the rights to develop, manufacture
The two companies are already working together after Novartis signed an in-licensing agreement for BeiGene’s anti-PD-1 monoclonal antibody, tislelizumab. ... Novartis is advancing tislelizumab as a potential ‘bridge to enable synergistic
This is our fifth positive phase 3 readout for tislelizumab, which we are developing broadly as a potentially differentiated anti-PD-1 antibody. ... In April, BeiGene also unveiled results from a key global trial of tislelizumab in non-small cell lung
More from news
Approximately 5 fully matching, plus 10 partially matching documents found.
The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and ... Tislelizumab is in global phase III trials in a number of tumour
It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...